Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Fish and Richardson
Harvard Business School
Citi
Federal Trade Commission
US Army
Teva
Deloitte
Argus Health
Chubb

Generated: January 24, 2019

DrugPatentWatch Database Preview

RUBRACA Drug Profile

« Back to Dashboard

Summary for RUBRACA
Drug patent expirations by year for RUBRACA
Generic Entry Opportunity Date for RUBRACA
Generic Entry Date for RUBRACA*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
TABLET;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for RUBRACA
Synonyms for RUBRACA
283173-50-2
6-FLUORO-2-{4-[(METHYLAMINO)METHYL]PHENYL}-3,10-DIAZATRICYCLO[6.4.1.0?,(1)(3)]TRIDECA-1,4(13),5,7-TETRAEN-9-ONE
6H-Azepino(5,4,3-cd)indol-6-one, 8-fluoro-1,3,4,5-tetrahydro-2-(4-((methylamino)methyl)phenyl)-
6H-Pyrrolo(4,3,2-ef)(2)benzazepin-6-one, 8-fluoro-1,3,4,5-tetrahydro-2-(4-((methylamino)methyl)phenyl)-
6H-Pyrrolo[4,3,2-ef][2]benzazepin-6-one,8-fluoro-1,3,4,5-tetrahydro-2-[4-[(methylamino)methyl]phenyl]-
8-FLUOR-2-{4-[(METHYLAMINO)METHYL]FENYL}-1,3,4,5-TETRAHYDRO-6HAZEPINO[5,4,3-CD]INDOOL-6-ON
8-Fluoro-1,3,4,5-tetrahydro-2-[4-[(methylamino)methyl]phenyl]-6H-pyrrolo[4,3,2-ef][2]benzazepin-6-one
8-Fluoro-2-(4-((methylamino)methyl)phenyl)-1,3,4,5-tetrahydro-6H-azepino(5,4,3-cd)indol-6-one
8-FLUORO-2-(4-((METHYLAMINO)METHYL)PHENYL)-4,5-DIHYDRO-1H-AZEPINO[5,4,3-CD]INDOL-6(3H)-ONE
8-fluoro-2-(4-methylaminomethyl-phenyl)-1,3,4,5-tetrahydro-azepino[5,4,3-cd]indol-6-one
8-Fluoro-2-[4-[(methylamino)methyl]phenyl]-1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one
8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one
8237F3U7EH
AC-24390
AG 014699
AG-14447
AG14447
AK317822
AKOS015898427
BDBM50446130
BRD-K88560311-011-01-4
CHEBI:134689
CHEBI:94311
CHEMBL1173055
CS-2785
CTK4G1217
D01SHZ
D10079
DB12332
DTXSID10182563
FT-0696622
GTPL7736
HMABYWSNWIZPAG-UHFFFAOYSA-N
HY-10617A
I10-0690
KB-73984
Kinome_3180
MolPort-028-744-762
NCGC00263173-01
NCGC00263173-03
PF 01367338
PF01367338
PL006099
RPB
Rubraca (TN)
RUCAPARIB
Rucaparib (free base)
Rucaparib (USAN/INN)
Rucaparib [USAN:INN]
Rucaparib(AG-014447)
SCHEMBL844585
Tube725
UNII-8237F3U7EH
Z-3241
ZINC25958

US Patents and Regulatory Information for RUBRACA

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Clovis Oncology Inc RUBRACA rucaparib camsylate TABLET;ORAL 209115-002 Dec 19, 2016 RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Clovis Oncology Inc RUBRACA rucaparib camsylate TABLET;ORAL 209115-003 May 1, 2017 RX Yes No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Clovis Oncology Inc RUBRACA rucaparib camsylate TABLET;ORAL 209115-002 Dec 19, 2016 RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Clovis Oncology Inc RUBRACA rucaparib camsylate TABLET;ORAL 209115-003 May 1, 2017 RX Yes No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Clovis Oncology Inc RUBRACA rucaparib camsylate TABLET;ORAL 209115-002 Dec 19, 2016 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Clovis Oncology Inc RUBRACA rucaparib camsylate TABLET;ORAL 209115-003 May 1, 2017 RX Yes No ➤ Sign Up ➤ Sign Up Y Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Supplementary Protection Certificates for RUBRACA

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2015016,C1633724 Lithuania ➤ Sign Up PRODUCT NAME: OLAPARIBAS IR JO DRUSKOS IR SOLVATAI; REGISTRATION NO/DATE: EU/1/14/959 20141216
0150012 00136 Estonia ➤ Sign Up PRODUCT NAME: OLAPARIIB;REG NO/DATE: EU/1/14/959 18.12.2014
500012 Hungary ➤ Sign Up PRODUCT NAME: OLAPARIB
2015 00012 Denmark ➤ Sign Up PRODUCT NAME: OLAPARIB, OG SALTE OG SOLVATER DERAF; REG. NO/DATE: EU/1/14/959/001 20141216
C0022 France ➤ Sign Up PRODUCT NAME: OLAPARIB,SELS ET SOLVATES DE CELUI-CI; REGISTRATION NO/DATE: EU 1/14/959 20141218
90019-4 Sweden ➤ Sign Up PRODUCT NAME: OLAPARIB, AND SALTS AND SOLVATES THEREOF; REG. NO/DATE: EU/1/14/959 20141218
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Argus Health
Fish and Richardson
Chubb
Healthtrust
Merck
Deloitte
Covington
Chinese Patent Office
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.